Adalvo’s purchase of Enzene’s Nplate biosimilar program extends it into biologics and moves Enzene toward a CDMO-only model.
News|Articles|April 16, 2026
ADC Manufacturing: Navigating 5 Overlooked Challenges
This practical guide sheds light on often underestimated risks in ADC fluid and cold chain management – including cytotoxic exposure, operator safety, precision filling, freeze thaw stress, bioprocess container breakages, and costs. It outlines how closed, automated, and controlled single use systems help reduce risk, improve process reliability, and preserve ADC quality across fluid handling and cold chain operations.
Related to this article
At AAPS PharmSci 360, Thermo Fisher Scientific scientists described how predictive modeling guides technology selection for poorly soluble drugs, and outlined plans to bring solvent-free KinetiSol technology to commercial scale in 2027.
Speaking at AAPS PharmSci 360, Dr Stephanie Johnson, a principal formulation scientist at Pfizer, details how platform formulations save time before commitment, shift risk downstream, and what AI tools need to earn trust.
BMS and SystImmune’s bispecific ADC iza-bren nearly doubles progression-free survival in EGFR-mutated lung cancer, GSK and Hansoh’s B7-H3 ADC Ris-Rez extends progression-free survival in relapsed osteosarcoma, and Immatics’ TCR bispecific IMA402 posts a 32% response rate in PRAME-high tumors.
Phase 1b data at ESMO 2026 show the TCR-based T-cell engager produced durable responses in PRAME-high melanoma, with 91% of patients alive at one year in the recommended dose range.
In two small phase 1b trials, the half-life-extended bispecific antibody improved skin disease and reduced airway inflammation. Aclaris will move next into a Phase 2b trial in eosinophilic esophagitis.
Risvutatug rezetecan extended median progression-free survival to 5.5 months vs 1.4 months with chemotherapy in pretreated osteosarcoma.
Izalontamab brengitecan extended median progression-free survival to 11.1 months vs 5.7 months with chemotherapy after EGFR TKI failure.
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
3
The BioPharm Brief: Survival Gains, a Modest ADC Win, and CAR-T in Multiple Sclerosis
4
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
5